Takeda, Ovid team to develop epilepsy candidate

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (New York, N.Y.) partnered to develop the Japanese pharma’s TAK-935. Takeda has

Read the full 217 word article

User Sign In